Safety and Tolerability of Active Immunotherapy Targeting α-Synuclein with PD03A in Patients with Early Parkinson’s Disease: A Randomized, Placebo-Controlled, Phase 1 Study

BACKGROUND: Immunotherapies targeting α-synuclein aim to limit its extracellular spread in the brain and prevent progression of pathology in Parkinson’s disease (PD). PD03A is a specific active immunotherapy (SAIT) involving immunization with a short peptide formulation. OBJECTIVE: This phase 1 stud...

Descripción completa

Detalles Bibliográficos
Autores principales: Poewe, Werner, Volc, Dieter, Seppi, Klaus, Medori, Rossella, Lührs, Petra, Kutzelnigg, Alexandra, Djamshidian, Atbin, Thun-Hohenstein, Caroline, Meissner, Wassilios G., Rascol, Olivier, Schneeberger, Achim, Staffler, Günther, deMarzi, Roberto, Heim, Beatrice, Mangesius, Stephanie, Stolz, Raphaela, Wachowicz, Katarzyna, Riha, Constanze, Bürger, Vera, Galabova, Gergana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: IOS Press 2021
Materias:
Research Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8461711/
https://www.ncbi.nlm.nih.gov/pubmed/34092654
http://dx.doi.org/10.3233/JPD-212594

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8461711/
https://www.ncbi.nlm.nih.gov/pubmed/34092654
http://dx.doi.org/10.3233/JPD-212594

Ejemplares similares